PPH
VanEck Pharmaceutical ETF
VanEck Vectors Pharmaceutical ETF is an exchange-traded fund incorporated in the USA. The Fund seeks to track the performance of the US Listed Pharmaceutical 25 Index.
US
EQUITY
Passive
MANAGEMENT STYLE
$ 1.1 B
ASSETS UNDER MGMT
36 bp
EXPENSES
Fund Basics
| Inception date | Dec 20, 2011 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 21.7 % |
| MERCK & CO. INC. | 12.7 % |
| NOVO-NORDISK A/S-SPONS ADR | 5.5 % |
| PFIZER INC | 5.2 % |
| MCKESSON CORP | 4.8 % |
| BRISTOL-MYERS SQUIBB CO | 4.6 % |
| TEVA PHARMACEUTICAL-SP ADR | 4.5 % |
| GLAXOSMITHKLINE PLC-SPON ADR | 4.5 % |
| CENCORA INC | 4.4 % |
| HALEON PLC | 4.0 % |
Constituent Breakdown
| Number of holdings | 27 |
| Herfindahl-Hirschman Index | 889 |
| Wgt avg mkt cap (mns) | $375,409 |
| Large cap (>$10bn) | 94.5% |
| Mid cap ($2-10bn) | 1.4% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 95.9% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 66.8 % |
 |
BRITAIN | 8.1 % |
 |
DENMARK | 5.5 % |
 |
ISRAEL | 4.5 % |
 |
SWITZERLAND | 3.6 % |
 |
FRANCE | 3.2 % |
 |
JAPAN | 2.9 % |
 |
IRELAND | 1.3 % |
Historical Performance
Standardized Performance (as of 09/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 6.1% | 21.1% | 7.3% | 11.1% | 8.5% | 6.7% | -- | 7.9% |
| Dividend Yield | 1.5% | 2.6% | 2.3% | 2.3% | 2.2% | 2.0% | -- | 2.6% |
| Total Returns | 7.6% | 23.7% | 9.7% | 13.4% | 10.7% | 8.7% | -- | 10.5% | Ann. Volatility | 18.8% | 18.4% | 18.3% | 16.3% | 15.7% | 17.1% | -- | 16.3% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.28 | 4% |
| MSCI EAFE | 0.43 | 14% |
| MSCI Emg Mkts | 0.03 | 0% |
Liquidity Measures
| Avg. volume (000) | 423 |
| ADV traded (mns) | $50 |
| Turnover | 4.6% |
| Avg. Bid/Ask (% of price) | 0.02% |
Technical Indicators
| 30d moving avg. (EMA) | $112.19 |
| Relative strength (RSI) | 56 |
| MACD/Signal | 1.33/0.64 |
| Bollinger Bands (Upper/Lower) | $117.40/$105.60 |
| Short interest (% of AUM) | 32.6% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PPH |
Expenses vs. PPH |
ALTAR Score™ vs. PPH |
|---|---|---|---|---|
| IHE | iShares U.S. Pharmaceuticals ETF | 45.9% | +1 bp | -1.7% |
| MEDX | Horizon Kinetics Medical ETF | 45.1% | +49 bp | -6.0% |
| XLV | Health Care Select Sector SPDR | 36.4% | -28 bp | -1.0% |
| PBPH | Portfolio Building Block World Pharma and Biotech Index ETF | 36.0% | -23 bp | -1.2% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 35.8% | +24 bp | -1.4% |
| IYH | iShares U.S. Healthcare ETF | 33.2% | +1 bp | -1.7% |
| VHT | Vanguard Health Care ETF | 33.1% | -27 bp | -2.3% |
| FHLC | Fidelity MSCI Health Care Index ETF | 32.9% | -28 bp | -2.2% |
| MEDI | Harbor Health Care ETF | 31.0% | +44 bp | -7.6% |
| THNR | Amplify Weight Loss Drug & Treatment ETF | 30.7% | +23 bp | -2.8% |
Risk and Returns: PPH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 11/1/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
7.0%
ALTAR SCORE™
76th
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 1,400 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. PPH's ALTAR Score™ is approximately 0.7 standard
deviations above the category average. This places PPH in the 76th percentile
among funds in the category.
Sell-Side Consensus
$128.54
PRICE TARGET
+7.7%
UPSIDE